Scholars@Duke
Payal Kohli

Payal Kohli

Adjunct Associate Professor in the Department of Medicine
Medicine, Cardiology

Selected Publications

Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines.

Journal Article Am J Med · February 2024 The 2023 American Heart Association/American College of Cardiology Multisociety Guideline for the Management of Patients with Chronic Coronary Disease provides updated recommendations for the management of chronic coronary disease. The term "chronic corona ... Full text Link to item Cite

COVID's Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us.

Journal Article Curr Cardiol Rep · July 2022 PURPOSE OF REVIEW: In this review, we outline the impacts of the COVID-19 pandemic on non-communicable diseases around the world. RECENT FINDINGS: The mechanisms of COVID-19's impact on non-communicable diseases are both direct and indirect. The direct mec ... Full text Open Access Link to item Cite

Popular Media and Cardiovascular Medicine: "with Great Power There Must Also Come Great Responsibility".

Journal Article Curr Atheroscler Rep · October 31, 2019 PURPOSE OF REVIEW: Media sources, such as the Internet, television, and social media, have become powerful communication tools that have transformed the way medical information is acquired across the world. RECENT FINDINGS: Over 40% of today's patients rep ... Full text Link to item Cite

Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials.

Journal Article Curr Atheroscler Rep · January 10, 2019 PURPOSE OF REVIEW: Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this ... Full text Link to item Cite

Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials).

Journal Article Am J Cardiol · November 1, 2016 The goal of this analysis was to evaluate the ability of insulin resistance, identified by the presence of prediabetes mellitus (PreDM) combined with either an elevated triglyceride (TG >1.7 mmol/l) or body mass index (BMI ≥27.0 kg/m2), to identify increas ... Full text Open Access Link to item Cite

Hypertriglyceridemia: A simple approach to identify insulin resistance and enhanced cardio-metabolic risk in patients with prediabetes.

Journal Article Diabetes Res Clin Pract · October 2016 AIMS: Prediabetes (PreDM) is a metabolically heterogeneous condition, differing in degree of insulin resistance and risk of type 2 diabetes mellitus and coronary heart disease (CHD). This study was initiated to evaluate the hypothesis that a fasting plasma ... Full text Link to item Cite

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).

Journal Article Am J Cardiol · August 15, 2016 Whether biomarkers associated with cardiovascular disease risk also predict incident diabetes mellitus (DM) is unknown. Our objective was to determine if a panel of 18 biomarkers previously associated with risk of cardiovascular disease also predicts incid ... Full text Link to item Cite

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".

Journal Article J Am Heart Assoc · April 29, 2016 BACKGROUND: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events and have hig ... Full text Open Access Link to item Cite

Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.

Journal Article Catheter Cardiovasc Interv · February 15, 2016 BACKGROUND: Outcomes with bivalirudin compare favorably with heparin ± GPIIb/IIIa receptor inhibition (heparin ± GPI) during percutaneous coronary intervention (PCI). Patients with congestive heart failure (CHF) have increased risk for complications. The o ... Full text Link to item Cite

Right Ventricular Anatomy

Chapter · January 1, 2015 Full text Cite

Clinician's guide to the updated ABCs of cardiovascular disease prevention.

Journal Article J Am Heart Assoc · September 22, 2014 To facilitate the guideline-based implementation of treatment recommendations in the ambulatory setting and to encourage participation in the multiple preventive health efforts that exist, we have organized several recent guideline updates into a simple AB ... Full text Open Access Link to item Cite

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).

Journal Article J Am Coll Cardiol · February 11, 2014 OBJECTIVES: This study sought to define the ability of AMG 145, a monoclonal antibody directed against proprotein convertase subtilisin kexin type 9 (PCSK9), to enable subjects at high risk for major adverse cardiovascular events to achieve National Choles ... Full text Link to item Cite

Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).

Journal Article J Am Coll Cardiol · January 28, 2014 OBJECTIVES: The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibitio ... Full text Link to item Cite

NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.

Journal Article Am J Med · January 2014 BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) other than aspirin have been linked to heart failure, salt retention, adverse ventricular remodeling, and thrombosis. We therefore sought to assess their impact on cardiovascular events in outpatien ... Full text Link to item Cite

ECG quiz.

Journal Article J Electrocardiol · 2014 Full text Link to item Cite

Relation of hepatic steatosis to atherogenic dyslipidemia.

Journal Article Am J Cardiol · November 15, 2013 Hepatic steatosis is closely associated with the metabolic syndrome. We assessed for an independent association between hepatic steatosis and atherogenic dyslipidemia after adjustment for obesity, physical activity, hyperglycemia, and systemic inflammation ... Full text Link to item Cite

Vini, vidi, vici... restructured format for condensed abstracts.

Journal Article JACC Cardiovasc Imaging · November 2013 Full text Link to item Cite

Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.

Journal Article Clin Cardiol · September 2013 Although atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B-containi ... Full text Link to item Cite

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Journal Article Circulation · August 27, 2013 BACKGROUND: Lipoprotein(a) [Lp(a)] is an emerging risk factor for cardiovascular disease. Currently, there are few available therapies to lower Lp(a). We sought to evaluate the impact of AMG145, a monoclonal antibody against proprotein convertase subtilisi ... Full text Link to item Cite

A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.

Journal Article Clin Cardiol · July 2013 Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. Fortunately, it is often preventable with early adoption of lifestyle modification, prevention of risk factor onset, and aggressive treatment of ... Full text Open Access Link to item Cite

Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.

Journal Article J Cardiovasc Pharmacol Ther · May 2013 Dyslipidemia is a major risk factor for the development of coronary artery disease, a leading cause of morbidity and mortality worldwide. Lowering low-density lipoprotein (LDL) has significantly reduced the risk of death and other major cardiovascular even ... Full text Link to item Cite

Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.

Journal Article Circulation · February 12, 2013 BACKGROUND: We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as ... Full text Link to item Cite

Dabigatran associated with increased risk of acute coronary events

Journal Article Evidence-Based Medicine · February 1, 2013 Full text Cite

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Journal Article Lancet · December 8, 2012 BACKGROUND: LDL cholesterol (LDL-C) is a well established risk factor for cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, targeting them for degradation. We therefore assessed the efficacy, safety, and tol ... Full text Link to item Cite

The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data.

Journal Article Clin Cardiol · December 2012 Results from different types of clinical research studies provide different types of evidence for evaluating the effects of a new drug or intervention. For this reason, it is important to recognize this phenomenon during reporting and to choose appropriate ... Full text Link to item Cite

Danger ahead: watch out for indirect comparisons!

Journal Article J Am Coll Cardiol · August 21, 2012 Full text Link to item Cite

Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.

Journal Article Expert Opin Drug Metab Toxicol · July 2012 INTRODUCTION: Arterial and venous thrombotic states, including myocardial infarction (MI), stroke and deep vein thrombosis with subsequent pulmonary embolism, are a significant cause of cardiovascular mortality and morbidity. Factor Xa (FXa) plays a pivota ... Full text Link to item Cite

Cost-effective medicines for stroke prophylaxis in patients with atrial fibrillation

Journal Article Journal of Atrial Fibrillation · June 1, 2012 Non-valvular atrial fibrillation is the most common arrhythmia encountered in clinical practice and is associated with substantial healthcare costs. The risk of thromboembolic stroke is 3-5 times higher in patients with atrial fibrillation compared with th ... Cite

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.

Journal Article Clin Cardiol · 2012 Lowering low-density lipoprotein cholesterol (LDL-C) is a cornerstone for the prevention of atherosclerotic heart disease, improving clinical outcomes and reducing vascular mortality in patients with hypercholesterolemia. The clinical benefits of LDL-C red ... Full text Open Access Link to item Cite

Triglycerides: how much credit do they deserve?

Journal Article Med Clin North Am · January 2012 In the modern era of statin therapy, major advances have been made in treating coronary heart disease. However, despite intensive treatment with statin therapy, residual cardiovascular risk persists and has been attributed to the persistence of atherogenic ... Full text Link to item Cite

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.

Journal Article Clin Chem · January 2012 OBJECTIVE: We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial. BACKGROUND: Myocytes that ar ... Full text Open Access Link to item Cite

Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.

Journal Article Nat Rev Cardiol · December 20, 2011 Major advances in the diagnosis of acute coronary syndromes (ACS) have occurred in 2011, but physicians treating ACS still walk the tightrope between efficacy and bleeding. Key publications have shed light on this delicate balance and heralded a new era of ... Full text Link to item Cite

Resolvins and protectins: mediating solutions to inflammation.

Journal Article Br J Pharmacol · October 2009 Resolution of inflammation has historically been viewed as a passive process, occurring as a result of the withdrawal of pro-inflammatory signals, including lipid mediators such as leukotrienes and prostaglandins. Thus, most anti-inflammatory drugs have tr ... Full text Link to item Cite

Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness.

Journal Article J Immunol · January 1, 2007 Protectins are newly identified natural chemical mediators that counter leukocyte activation to promote resolution of inflammation. In this study, we provide the first evidence for protectin D1 (PD1, 10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic ... Full text Link to item Cite

Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury.

Journal Article J Immunol · April 15, 2005 Acute lung injury (ALI) is a severe illness with excess mortality and no specific therapy. In its early exudative phase, neutrophil activation and accumulation in the lung lead to hypoxemia, widespread tissue damage, and respiratory failure. In clinical tr ... Full text Link to item Cite